- Home
- ANGH vs CTSO Comparison
ANGH vs CTSO Comparison
Compare ANGH & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- CTSO
- Stock Information
- Founded
- ANGH 2012
- CTSO 1997
- Country
- ANGH United Arab Emirates
- CTSO United States
- Employees
- ANGH N/A
- CTSO N/A
- Industry
- ANGH Telecommunications Equipment
- CTSO Medical/Dental Instruments
- Sector
- ANGH Consumer Discretionary
- CTSO Health Care
- Exchange
- ANGH Nasdaq
- CTSO Nasdaq
- Market Cap
- ANGH 46.8M
- CTSO 51.6M
- IPO Year
- ANGH N/A
- CTSO N/A
- Fundamental
- Price
- ANGH $0.69
- CTSO $1.15
- Analyst Decision
- ANGH
- CTSO Strong Buy
- Analyst Count
- ANGH 0
- CTSO 3
- Target Price
- ANGH N/A
- CTSO $4.67
- AVG Volume (30 Days)
- ANGH 18.0K
- CTSO 147.4K
- Earning Date
- ANGH 02-28-2025
- CTSO 03-06-2025
- Dividend Yield
- ANGH N/A
- CTSO N/A
- EPS Growth
- ANGH N/A
- CTSO N/A
- EPS
- ANGH N/A
- CTSO N/A
- Revenue
- ANGH $52,274,011.00
- CTSO $37,739,531.00
- Revenue This Year
- ANGH N/A
- CTSO $9.20
- Revenue Next Year
- ANGH N/A
- CTSO $11.64
- P/E Ratio
- ANGH N/A
- CTSO N/A
- Revenue Growth
- ANGH 13.03
- CTSO 1.80
- 52 Week Low
- ANGH $0.62
- CTSO $0.70
- 52 Week High
- ANGH $2.27
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- ANGH 44.92
- CTSO 55.74
- Support Level
- ANGH $0.63
- CTSO $1.06
- Resistance Level
- ANGH $0.72
- CTSO $1.61
- Average True Range (ATR)
- ANGH 0.05
- CTSO 0.13
- MACD
- ANGH 0.00
- CTSO 0.01
- Stochastic Oscillator
- ANGH 42.31
- CTSO 29.34
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with the catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner and is continuously licensing new content.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.